Atsena Therapeutics Announces Late-Breaker Presentation at the American Academy of Ophthalmology 2022 Annual Meeting
Data from Phase I/II trial of ATSN-101 in patients with GUCY2D-associated Leber congenital amaurosis (LCA1) to be presented
DURHAM, N.C., Sept. 21, 2022 (GLOBE NEWSWIRE) -- Atsena Therapeutics, a clinical-stage gene therapy company focused on bringing the life-changing power of genetic medicine to reverse or prevent blindness, today announced that data from the Phase I/II clinical trial of ATSN-101 will be presented in a Late Breaking Developments session during the Retina Subspecialty Day at the American Academy of Ophthalmology Annual Meeting (AAO 2022), which is being held September 30 - October 3, 2022 in Chicago.
ATSN-101, Atsena’s lead investigational gene therapy product formerly known as SAR439483, is being evaluated in patients with Leber congenital amaurosis caused by biallelic mutations in GUCY2D (LCA1). LCA1 is a monogenic eye disease that disrupts the function of the retina and results in early and severe vision impairment or blindness.
Details of the presentation are as follows:
Title: Safety and Efficacy of SAR439483 in Patients with Leber Congenital maurosis Caused by Biallelic Mutations in GUCY2D (LCA1)
Section: Section X: Late Breaking Developments, Part II
Date / Time: Saturday, October 1, 9:15 a.m. CST
Location: McCormick Place – Arie Crown
Presenter: Christine Nichols Kay, MD, Atsena Therapeutics
About Atsena Therapeutics